Search Results 121-130 of 17208 for hba1c

1. A Study of the Effects of a Nocturnal Rise in Cortisol on Glucose Production in Type 2 Diabetes - Mayo Clinic

   ... HbA1c <10%; Subjects on thiazolidinediones may be included if they agree to stop these medications for at least 3-4 weeks before study visits; All women of ...

2. Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen - Mayo Clinic

   Poorly controlled diabetes mellitus defined as having a HbA1c ≥8.5% (ie, ≥69.5 mmol/mol) or estimated HbA1c based on fructosamine if HbA1c is not evaluable ( ...

3. Insulin and weight gain: Keep the pounds off - Mayo Clinic

   Understand why weight gain is linked to insulin treatment, and find out how to dodge those extra pounds while still managing your blood sugar.

4. A Phase 2b, Study Of Linsitinib In Subjects With Active, Moderate To Severe Thyroid Eye Disease (TED) - Mayo Clinic

   Diabetic subjects must have HbA1c < 9.0%. Type 2 diabetic subjects who are not on insulin, must not be prescribed insulin within 60 days prior to screening ...

5. Effect Of TAK-954 On Gastrointestinal And Colonic Transit In Diabetic Or Idiopathic Gastroparesis Participants - Mayo Clinic

   Participation eligibility · Have glycosylated hemoglobin (HbA1c) greater than (>) 12 percent (%). · Have other structural diseases/conditions that affect the ...

6. A Study To Evaluate Setmelanoitide To Treat Patients With Rare Genetic Disorders Of Obesity - Mayo Clinic

   Any patient with a potentially clinically significant disease should be reviewed with the Sponsor to determine eligibility. HbA1c >9.0% at Screening ...

7. Automated Insulin Delivery in Elderly with Type 1 Diabetes - Mayo Clinic

   HbA1c < 10.0% from point of care or local lab at time of screening visit. Insulin regimen involves basal/bolus insulin via insulin pump or multiple daily ...

8. https://www.mayoclinic.org/arabic_procedure_concepts.xml

9. A Study To Evaluate The Safety And Effectiveness Of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant As Treatment For Locally Advanced (Inoperable) Or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer - Mayo Clinic

   HbA1c ≥ 8.0% (63.9 mmol/mol). Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular ...

10. A Study Of The Effects Of Inflammation On Fat Tissue And Insulin In People With Different Body Shapes - Mayo Clinic

    For Type II Diabetic volunteers they will need a HbA1C between 7.0% and 9.5%. As with obese participants (above), transaminase, glucose and lipid values are ...